Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy
The introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibition. One reason for this is activation of extravas...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-09-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/938 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850024600674500608 |
|---|---|
| author | M. V. Marchenko O. U. Klimova E. V. Anikina A. V. Lapina T. A. Rudakova T. I. Ksenzova A. D. Kulagin |
| author_facet | M. V. Marchenko O. U. Klimova E. V. Anikina A. V. Lapina T. A. Rudakova T. I. Ksenzova A. D. Kulagin |
| author_sort | M. V. Marchenko |
| collection | DOAJ |
| description | The introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibition. One reason for this is activation of extravascular hemolysis, due to opsonization of erythrocytes with fragments of the C3 component. Pegcetacoplan, the first ever registered C3 inhibitor, is aimed at solving this problem.In Russia, 2 patients received pegcetacoplan as part of a phase 3, randomized, open-label, active-comparator controlled trial PEGASUS. The analysis includes data from the first year of therapy: the run-in period (pegcetacoplan 1080 mg SC twice weekly in addition to the current dose of eculizumab, 4 weeks), the randomized controlled period (both patients were randomized to eculizumab monotherapy, 16 weeks), and the open-label period of pegcetacoplan therapy (32 weeks). Data from the extension study to evaluate the long-term safety and efficacy of pegcetacoplan are also presented. The duration of follow-up on pegcetacoplan therapy in both patients exceeded 4 years. |
| format | Article |
| id | doaj-art-71420cfe4cba44df9b8161e886d0f53e |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2024-09-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-71420cfe4cba44df9b8161e886d0f53e2025-08-20T03:01:03ZrusABV-pressОнкогематология1818-83462413-40232024-09-01193687810.17650/1818-8346-2024-19-3-68-78765Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapyM. V. Marchenko0O. U. Klimova1E. V. Anikina2A. V. Lapina3T. A. Rudakova4T. I. Ksenzova5A. D. Kulagin6Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRegional Clinical Hospital No. 1Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRaisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaRegional Clinical Hospital No. 1Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of RussiaThe introduction of the complement component C5 inhibitor eculizumab has radically changed the prognosis and quality of life of patients with paroxysmal nocturnal hemoglobinuria. Up to 30 % of patients develop only a suboptimal response to C5 inhibition. One reason for this is activation of extravascular hemolysis, due to opsonization of erythrocytes with fragments of the C3 component. Pegcetacoplan, the first ever registered C3 inhibitor, is aimed at solving this problem.In Russia, 2 patients received pegcetacoplan as part of a phase 3, randomized, open-label, active-comparator controlled trial PEGASUS. The analysis includes data from the first year of therapy: the run-in period (pegcetacoplan 1080 mg SC twice weekly in addition to the current dose of eculizumab, 4 weeks), the randomized controlled period (both patients were randomized to eculizumab monotherapy, 16 weeks), and the open-label period of pegcetacoplan therapy (32 weeks). Data from the extension study to evaluate the long-term safety and efficacy of pegcetacoplan are also presented. The duration of follow-up on pegcetacoplan therapy in both patients exceeded 4 years.https://oncohematology.abvpress.ru/ongm/article/view/938paroxysmal nocturnal hemoglobinuriacomplement c5 inhibitorsuboptimal responsecomplement c3 inhibitorpegcetacoplan |
| spellingShingle | M. V. Marchenko O. U. Klimova E. V. Anikina A. V. Lapina T. A. Rudakova T. I. Ksenzova A. D. Kulagin Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy Онкогематология paroxysmal nocturnal hemoglobinuria complement c5 inhibitor suboptimal response complement c3 inhibitor pegcetacoplan |
| title | Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy |
| title_full | Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy |
| title_fullStr | Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy |
| title_full_unstemmed | Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy |
| title_short | Complement C3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to C5 inhibitor therapy |
| title_sort | complement c3 inhibitor in patients with paroxysmal nocturnal hemoglobinuria with suboptimal response to c5 inhibitor therapy |
| topic | paroxysmal nocturnal hemoglobinuria complement c5 inhibitor suboptimal response complement c3 inhibitor pegcetacoplan |
| url | https://oncohematology.abvpress.ru/ongm/article/view/938 |
| work_keys_str_mv | AT mvmarchenko complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy AT ouklimova complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy AT evanikina complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy AT avlapina complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy AT tarudakova complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy AT tiksenzova complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy AT adkulagin complementc3inhibitorinpatientswithparoxysmalnocturnalhemoglobinuriawithsuboptimalresponsetoc5inhibitortherapy |